Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897595555> ?p ?o ?g. }
- W2897595555 endingPage "7368" @default.
- W2897595555 startingPage "7353" @default.
- W2897595555 abstract "Enzalutamide-resistant castration resistant prostate cancer: challenges and solutions Marcello Tucci,1,* Clizia Zichi,1,* Consuelo Buttigliero,1 Francesca Vignani,2 Giorgio V Scagliotti,1 Massimo Di Maio2 1Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10043 Orbassano, Turin, Italy; 2Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy *These authors contributed equally to this work Abstract: The new-generation hormonal agent enzalutamide has been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), in both post- and predocetaxel setting, due to the significant improvement in overall survival. More recently, enzalutamide also showed impressive results in the treatment of men with nonmetastatic CRPC. Unfortunately, not all patients with CRPC are responsive to enzalutamide, and even in responders, benefits are limited by the development of drug resistance. Adaptive resistance of metastatic prostate cancer to enzalutamide treatment can be due to the activation of both androgen receptor (AR)-dependent pathways (expression of constitutively active AR splice variants, AR point mutations, gene amplification and overexpression) and mechanisms independent of AR signaling pathway (altered steroidogenesis, upregulation of the glucocorticoid receptor, epithelial–mesenchymal transition, neuroendocrine transformation, autophagy and activation of the immune system). In this review, we focus on resistance mechanisms to enzalutamide, exploring how we could overcome them through novel therapeutic options. Keywords: prostate cancer, enzalutamide, hormonal treatment, mechanisms of resistance, castration-resistant prostate cancer, androgen receptor" @default.
- W2897595555 created "2018-10-26" @default.
- W2897595555 creator A5005250000 @default.
- W2897595555 creator A5007575010 @default.
- W2897595555 creator A5017771299 @default.
- W2897595555 creator A5030345469 @default.
- W2897595555 creator A5058429184 @default.
- W2897595555 creator A5079802303 @default.
- W2897595555 date "2018-10-01" @default.
- W2897595555 modified "2023-10-02" @default.
- W2897595555 title "Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions" @default.
- W2897595555 cites W1528881540 @default.
- W2897595555 cites W1557429377 @default.
- W2897595555 cites W1578291413 @default.
- W2897595555 cites W1582446028 @default.
- W2897595555 cites W1634543743 @default.
- W2897595555 cites W1907272683 @default.
- W2897595555 cites W1935981533 @default.
- W2897595555 cites W1964847767 @default.
- W2897595555 cites W1973890143 @default.
- W2897595555 cites W1979811833 @default.
- W2897595555 cites W1999343166 @default.
- W2897595555 cites W2004999965 @default.
- W2897595555 cites W2005302422 @default.
- W2897595555 cites W2007334137 @default.
- W2897595555 cites W2009171847 @default.
- W2897595555 cites W2009607678 @default.
- W2897595555 cites W2017919614 @default.
- W2897595555 cites W2024432096 @default.
- W2897595555 cites W2033184480 @default.
- W2897595555 cites W2051967652 @default.
- W2897595555 cites W2055346449 @default.
- W2897595555 cites W2059886358 @default.
- W2897595555 cites W2073100248 @default.
- W2897595555 cites W2077301757 @default.
- W2897595555 cites W2080748037 @default.
- W2897595555 cites W2080989291 @default.
- W2897595555 cites W2084637523 @default.
- W2897595555 cites W2091266023 @default.
- W2897595555 cites W2097226696 @default.
- W2897595555 cites W2098706602 @default.
- W2897595555 cites W2103959341 @default.
- W2897595555 cites W2105129152 @default.
- W2897595555 cites W2107633226 @default.
- W2897595555 cites W2110194568 @default.
- W2897595555 cites W2110534364 @default.
- W2897595555 cites W2117857186 @default.
- W2897595555 cites W2118018514 @default.
- W2897595555 cites W2120012330 @default.
- W2897595555 cites W2120457254 @default.
- W2897595555 cites W2121098984 @default.
- W2897595555 cites W2121846636 @default.
- W2897595555 cites W2123526148 @default.
- W2897595555 cites W2129442897 @default.
- W2897595555 cites W2130955565 @default.
- W2897595555 cites W2131146826 @default.
- W2897595555 cites W2134988422 @default.
- W2897595555 cites W2141454098 @default.
- W2897595555 cites W2148643283 @default.
- W2897595555 cites W2150468578 @default.
- W2897595555 cites W2150865892 @default.
- W2897595555 cites W2156923287 @default.
- W2897595555 cites W2160463964 @default.
- W2897595555 cites W2160844431 @default.
- W2897595555 cites W2161546209 @default.
- W2897595555 cites W2166324735 @default.
- W2897595555 cites W2166435610 @default.
- W2897595555 cites W2166918329 @default.
- W2897595555 cites W2206188372 @default.
- W2897595555 cites W2214621962 @default.
- W2897595555 cites W2235405584 @default.
- W2897595555 cites W2261870911 @default.
- W2897595555 cites W2268281268 @default.
- W2897595555 cites W2271989793 @default.
- W2897595555 cites W2340799873 @default.
- W2897595555 cites W2340829607 @default.
- W2897595555 cites W2345499901 @default.
- W2897595555 cites W2346677152 @default.
- W2897595555 cites W2403998898 @default.
- W2897595555 cites W2463867199 @default.
- W2897595555 cites W2473747534 @default.
- W2897595555 cites W2504612473 @default.
- W2897595555 cites W2507921127 @default.
- W2897595555 cites W2511121263 @default.
- W2897595555 cites W2518043457 @default.
- W2897595555 cites W2571250257 @default.
- W2897595555 cites W2588126825 @default.
- W2897595555 cites W2590318769 @default.
- W2897595555 cites W2611637096 @default.
- W2897595555 cites W2611922828 @default.
- W2897595555 cites W2613332942 @default.
- W2897595555 cites W2613775504 @default.
- W2897595555 cites W2616577186 @default.
- W2897595555 cites W2620746860 @default.
- W2897595555 cites W2620798309 @default.
- W2897595555 cites W2622254362 @default.
- W2897595555 cites W2711147105 @default.
- W2897595555 cites W2737056430 @default.